I-hung Shih
Co-Head, Biotech Private Investments

I-Hung is co-head of Wellington’s Biotech Private Investments Team, leading investment sourcing, diligence, and execution of investments in biotech companies seeking to improve the standard of care in medicine. She identifies innovative companies across the health care sector with lifesaving potential, such as high-impact drugs and therapies. 

Prior to joining Wellington Management in 2018, I-hung worked as a senior biotech analyst at T. Rowe Price covering US biotech stocks and a co-manager on the Institutional US Structured Research Fund (2016 – 2018). Previously, she was lead officer for US biopharma investment in public/private equity at Temasek International (2014 – 2016), and an associate in investment banking on the Credit Suisse Biotech Team (2011 – 2014). She began her professional career at Gilead Sciences as a research scientist in biology and a senior manager for commercial strategies (2005 – 2011). 

I-hung earned her MBA from The Wharton School, University of Pennsylvania (2011), her PhD in biochemistry from Duke University (2000), and her BS in chemistry from National Taiwan University (1995). She was also a research fellow at Whitehead Institute/Massachusetts Institute of Technology (2002 – 2005) and The National Institute of Health (2001 – 2002).

Insights By I-hung Shih